Reviewing INSYS Therapeutics Inc. (INSY)’s and Syros Pharmaceuticals Inc. (NASDAQ:SYRS)’s results

Both INSYS Therapeutics Inc. (NASDAQ:INSY) and Syros Pharmaceuticals Inc. (NASDAQ:SYRS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation Earnings

Table 1 highlights INSYS Therapeutics Inc. and Syros Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both companies.

Liquidity

The Current Ratio and Quick Ratio of INSYS Therapeutics Inc. are 0.7 and 0.6 respectively. Its competitor Syros Pharmaceuticals Inc.’s Current Ratio is 5.4 and its Quick Ratio is 5.4. Syros Pharmaceuticals Inc. can pay off short and long-term obligations better than INSYS Therapeutics Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for INSYS Therapeutics

... read more at: https://hinewulm.com/2019/04/14/reviewing-insys-therapeutics-inc-insys-and-syros-pharmaceuticals-inc-nasdaqsyrss-results/

by